Purpose This study compares the in vivo relative lung bioavailability of Hydrofluoroalkane (HFA) Seretide delivered via unprimed and unwashed Aerochamber Plus (AP) or Volumatic (VM) spacers, a integrated breathactuated vortex Synchro-Breathe (SB) device and an Evohaler pMDI (EH) device using adrenal suppression and early fall in serum potassium (K) as surrogates for respirable dose. Methods Seventeen healthy volunteers completed this randomised double-blind, double-dummy crossover study. Single doses of placebo/Seretide 250 (total dose ex valve fluticasone 2000 mcg/salmeterol 200 mcg) were administered via the devices. Overnight urinary cortisol/creatinine (OUCC) and serum K were measured at baseline and after each dose. Results Significant suppression of OUCC and K occurred from baseline with the SB, AP and VM but not with the EH devices. The geometric mean fold suppression (95% confidence interval, p) was: EH, 1.59 (0.80-3.14, p=0.40); AP, 4.26 (3.01-6.02, p<0.001); VM, 3.11 (1.99-4.78, p<0. 001); SB, 3.29 (2.04-5.24, p<0.001). For K, the arithmetic mean fall (mmol/l) (95% confidence interval; p) was: EH, Conclusions The breath-actuated SB device was comparable to 'out of the box' small and large volume spacers and produced similar improvements in relative systemic lung bioavailability for fluticasone and salmeterol.
Introduction
Valved holding chambers (VHC) or spacer devices are recommended for individuals who have problems coordinating actuation and inhalation of a pressurised metered dose inhaler devices (pMDI) [1, 2] . They increase the fine respirable dose fraction by causing impaction of larger particles within the walls of the holding chamber, reduce aerosol velocity and consequently reduce oropharyngeal deposition and local adverse effects. This leads to increased systemic drug absorption from the lung and results in increased systemic bioavailability which can be measured by using sensitive surrogates of systemic bioactivity [3] [4] [5] [6] [7] . The propensity for dose-related systemic and local adverse effects with inhaled corticosteroid therapy is often dictated by the choice of inhaled steroid, its pharmacokinetic and pharmacodynamic properties, its respirable particle size and site of lung deposition and type of drug delivery device used.
Fluticasone propionate (FP) and salmeterol (SM) are both highly lipophilic drugs that are commonly used to treat asthma. FP has negligible oral bioavailability on account of its near-complete hepatic first pass metabolism [8, 9] . Consequently, the systemic bioavailability of FP is dependant entirely on lung absorption and, therefore, the delivered lung dose. Suppression of the overnight urinary cortisol creatinine ratio (OUCC) following inhaled steroid therapy is a sensitive surrogate of relative lung dose delivery [3, 5, 10, 11] . Thus, reliable comparisons of the relative systemic bioavailability to the lung via different spacer devices can be made based on measurements of the OUCC. Similarly, SM, which is nearly eightfold more potent than salbutamol, has a high hepatic first pass metabolism and exhibits dose-dependent systemic beta-2-adrenoreceptor pharmacodynamic and pharmacokinetic effects which are predominantly due to the inhaled fraction [12, 13] . Maximal SM plasma concentration © max ) following inhalation predicts the maximal fall in potassium (K) [13] , and changes in serum K in particular are not significantly influenced by the swallowed SM fraction, which has been estimated to contribute 28-36% of systemic effects [12, 13] . Spacer devices further reduce the effect of the swallowed gut component to overall systemic bioavailability. Therefore, the early maximal fall in serum K occurs primarily due to lung absorption. As such, the relative lung bioavailability of SM via different devices can be reliably determined by measuring differences in the early fall of serum K.
Conventional VHC/spacer devices are bulky, cumbersome and therefore not attractive to most patients (Fig. 1) . Their operation is also influenced by the occurrence of electrostatic charge which can reduce the respirable dose delivery [14, 15] . In real life, patients would be unlikely to optimally prepare a new plastic spacer out of the box by performing either washing or priming manoeuvres, and so one might expect their performance to be initially suboptimal. In an earlier study, we evaluated a novel palm-sized antistatic breath-actuated vortex spacer device (SB; Synchro-Breathe; Vortran Medical Technology, Sacramento, CA) [7, 11] . This breath-actuated device has a reduced actuator orifice and unique integrated vortex extension which creates a turbulent ex-valve flow and a slower plume velocity when compared to the Seretide 250 Evohaler (pMDI). This alleviates any gagging due to throat impaction and could potentially improve compliance and drug delivery to the lung.
Having compared the relative systemic bioavailability to the lung of FP administered via an optimally prepared (washed and primed) AP spacer and combined FP/SM administered via a washed but unprimed Volumatic spacer to those delivered via pMDI and SynchroBreathe, respectively, we wanted to study the electrostatic impact of using conventional spacers that were brand new out of the box (i.e. without pre-washing or priming) on relative systemic bioavailability and, therefore, respirable dose delivery. To this end, we have evaluated the relative systemic bioavailability of Seretide 250 pMDI delivered to the lung via different delivery devices, namely, the conventional Evohaler (EH) pMDI alone, Synchro-Breathe (SB), an unprimed and unwashed 149-ml small volume Aerochamber Plus (AP) and an unprimed and unwashed 750-ml large volume plastic spacer [Volumatic (VM)], using OUCC and K as surrogates of relative lung delivery.
Methods

Patients
Nineteen non-smoking healthy participants between the ages of 18 and 65 years were recruited from our existing database of research volunteers. The Tayside Committee on Medical Research Ethics reviewed and approved the study protocol. The trial was registered in the European Clinical Trials Database.
Study design
This was a single centre, randomised double-blind, doubledummy study using a 4 way crossover design. The details of the randomisation and blinding process are given below. Each subject had three placebo pMDI canisters and one active Seretide pMDI canister which were independently labelled, blinded and packed under the supervision of the clinical trials pharmacist into separate treatment packs based on the computer-generated randomisation sequence available online at www. randomization.com. Evohaler actuators were used throughout except when SynchroBreathe devices was used. The placebo/active canisters were independently inserted into the Evohaler actuator and the Synchro-Breathe device prior to use. As the Evohaler, Aerochamber Plus, Volumatic and Synchro-Breathe devices are visually different, further blinding of the trial was realised via the double-dummy technique by using the pMDI via each of the four devices at each study visit. Thus, the participants and the researchers had no way of identifying which device was delivering the active drug even though they were all being used at each study visit. At the initial screening visit, the suitability of the device was checked and informed consent was obtained. The healthy volunteers then had a full physical examination, baseline spirometry, evaluation of routine biochemistry parameters, full blood count and electrocardiogram. If deemed suitable for inclusion, they were then randomised into the study and provided a pre-labelled container with written instructions on overnight urine collection. This container was brought in on the morning of the first study visit from each volunteer's residence by a taxi service so as to minimise patient visits and encourage compliance.
There were four treatment visits following screening, with between-visit intervals of 5-7 days (Fig. 2) to enable a steroid-free washout period with FP [16] . The study visits took place between 1500 and 1600 hours. At each of the study visits, the use of any concomitant medication(s) and occurrence of adverse event(s) were recorded. The optimal inhaler technique was demonstrated by the researcher and the technique reviewed at each study visit. An intravenous canula was inserted into the forearm ante-cubital vein and flushed with 10 ml of normal saline to maintain patency. An automated sphygmomanometer (Dinamap; Critikon, Tampa, FL), which records heart rate and blood pressure, was attached to the opposite arm. After 30 min of rest, a baseline sample (5 ml) of blood was collected, and three consecutive readings of heart rate and blood pressure recorded.
Thereafter, the following treatments were administered under direct supervision in a randomised double-blind, double-dummy fashion: eight puffs of Hydrofluoroalkane (HFA) placebo or an active FP/SM combination [Seretide 250: FP 250 mcg ex valve and SM 25 mcg ex valve per actuation; total dose ex valve FP 2000 mcg and SM 200 mcg] via the Evohaler pMDI, Aerochamber Plus, Volumatic and Synchro-Breathe spacer devices, respectively. We recognise that the dose used above does not reflect standard clinical practice in asthma; rather, it was chosen primarily to ensure that an adequate systemic signal in terms of suppression of OUCC and K was detectable in order to compare differences between devices.
The pMDIs used in the study were primed prior to first use by shaking them vigorously and discharging 5 puffs. Thereafter, the participants were asked to exhale to residual volume, and the inhaler was actuated at the beginning of inhalation; a steady, slow inhalation was maintained until total lung capacity, followed by breath holding for 10 s or for as long as possible. After 30 s, the procedure was repeated for the remaining doses. The pMDI canister was inserted into the SB, and the device was used in a similar manner to a conventional pMDI: the main difference was that the SB device was breath-actuated. The AP and VM spacers were used out of the box, brand new at each visit, and were not washed or primed prior to first use to simulate real life patient use. Single puffs were inhaled without delay between actuation and inhalation to optimise respirable dose delivery [14] . There was a 30-s delay between inhalations, and the procedure was repeated for each of the eight inhalations.
Measurements
Assessment of FP lung bioavailability Assessment of the OUCC was performed prior to the first study visit and following each study visit. All volunteers were given written instructions regarding overnight urine collection and were provided pre-labelled sealed urine containers. The volunteers were asked to empty their bladder at 1000 hours and to collect all of the voided urine until 0800 hours the next morning. The total volume of urine sample was recorded, and aliquots were taken for urinary cortisol and creatinine for overnight (10 h) urinary cortisol creatinine measurements. The procedure was repeated on the night following completion of drug inhalation at each of the study visits.
Assessment of SM lung bioavailability An intravenous canula was inserted into the ante-cubital vein at the start of the study visit, and all pharmacodynamic measurements of systemic beta-2 adrenoreceptor response were carried out with the participants in a semi-recumbent position and after 30 min of rest. Baseline serum K was collected; collection was repeated 1 h post-study drug inhalation to measure the early fall in K. Measurements of heart rate and blood pressure were taken in triplicate at baseline and at 15-min intervals for 60 min, with patients in a semi-recumbent position.
Assessment for adverse events A record of palpitations and visual analogue tremor scales was maintained at baseline and at 15-min intervals post-drug inhalation for 1 h in order to document immediate adverse effects to SM. Patients were also asked to report adverse events between study visits.
Assays
All assays were performed in duplicate in a blinded fashion. The urinary cortisol was measured using a commercial radioimmunoassay kit which has no cross reactivity for FP (Diasorin, Wokingham, Berkshire, UK). The intra-assay coefficient of variation was 4%, and the inter-assay coefficient of variation was 8%. Urinary creatinine was measured on a Cobas-Bio auto-analyzer (Roche Products, Welwyn Garden City, UK). The inter-and intra-assay coefficient of variation was 3 and 4.6%, respectively. Serum K was analyzed using the Roche Modular Multi ISE 1800 auto-analyzer (Roche Products), and the co-efficient of variation of the test was 1.2%
Statistical analysis
The primary endpoint was the overnight urinary cortisol creatinine ratio (OUCC). A sample size of 16 patients per protocol to completion was chosen to power the study at 80% in order to detect a 20% difference in the OUCC. This number was based on data from a previous study which detected a 50% difference between spacer and pMDI with a sample size of 14 patients who completed the study [17] .
Data sets were analysed for patients who completed the crossover study per protocol. All data were tested for normality prior to analysis. The OUCC data was log transformed, and K, heart rate, blood pressure data were analysed without transformation in view of its normal distribution. Comparisons were made using repeatedmeasures General Linear Model (GLM) analysis of variance with Bonferroni correction for multiple comparisons, set with 95% confidence intervals (CIs) for differences. All effects were reported as being significant at p < 0.05 (twotailed), and violation of sphericity of within-subject effects was tested with the Mauchly's test. The analysis was carried out using SPSS ver. 15 (SPSS, Chicago, IL).
Results
Nineteen healthy volunteers were randomised into the study, and 17 completed the study per protocol. One volunteer withdrew because of prolonged palpitations following the first study visit, and another was withdrawn due to his personal circumstances. The OUCC samples of two additional subjects were inconsistent on repeated assay testing and hence excluded from analysis, and two subjects were excluded from the K analysis as the samples were haemolysed. Baseline data are detailed in Table 1 and 2.
Significant suppression of OUCC (geometric mean fold suppression, 95% CI, p) and serum K occurred from baseline with the AP, VM and SB devices but not with the EH pMDI (Tables 3, 4) . Following combined FP/SM pMDI inhalation via the AP device, the geometric mean fold suppression (95% CI, p) of OUCC from baseline was 4.26 (3.01-6.02, p<0.001). There was a 3.11-fold (1.99-4.78, p<0.001) decrease via the VM, a 3.29-fold (2.04-5.24, p<0.001) decrease via the SB and a 1.59-fold decrease (0.80-3.14, p=0.4) via the EH pMDI (equating to 76.5, 67.8, 69.6 and 37% suppression via the AP, VM, Following study drug inhalation via all four devices, including the pMDI, there were significant increases in additional time course markers, namely, the systemic beta-2 adrenoreceptor response of maximal heart rate response, maximum increase in systolic BP and maximal fall in diastolic BP (Table 4 ).
Significant differences in OUCC suppression were demonstrated between the EH pMDI and AP, VM and SB devices (Table 5) . When compared to the EH pMDI, the AP device showed a 2.6-fold greater suppression of OUCC (95%CI 1.50-4.80, p<0.001). Similarly when compared to the EH pMDI, the VM device showed a 1.95-fold greater OUCC suppression (95% CI 1.09-3.46, p=0.01) and the SB resulted in a 2.06-fold greater suppression (95% CI 1.15-3.63, p =0.007) Equating to 62, 49 and 52% greater suppression than the EH pMDI by the AP, VM and SB devices, respectively). There were no significant differences in OUCC or K between spacer devices. However, there was a significant difference in the maximal heart rate response between SB and EH, and SB and VM; there were no significant differences between devices for changes in systolic and diastolic BP.
The following adverse events were reported by the study participants. Nine participants developed mild tremors, as assessed on the visual analogue scale, and these were observed on four occasions via the Aerochamber Plus and Volumatic spacers and on five occasions via the breathactuated Synchro-Breathe device. Three participants developed palpitations and one subject was withdrawn from the study due to discomforting tremors/palpitations.
Discussion
We have shown that the improvement in relative systemic bioavailability of fluticasone/salmeterol via the SynchroBreathe device is comparable to that of conventional small and large volume plastic spacers when used in new condition out of the box. We elected to make comparisons under real life conditions without pre-washing or priming of the new plastic spacers to assess if there was any effect of electrostatic charge during initial use. All three spacers significantly improved respirable drug dose delivery of FP/ SM from baseline when compared to the metered dose inhaler alone (Figs. 3, 4) .
There are limited data comparing the lung bioavailability of FP/SM pMDI via small and large volume spacers in either new or primed condition. In a previous study in which we evaluated the relative lung bioavailability of inhaled FP via washed and primed spacers in mild to moderate asthmatics, we found that the optimally primed and washed Aerochamber Plus spacer resulted in a 2.8-fold (65%) greater lung delivery compared to the pMDI and the breath-actuated Synchro-Breathe device resulted in a 1.59-fold (37%) greater lung delivery, again in terms of OUCC suppression [11] . To help tease out the effect of prewashing on relative systemic drug bioavailability, we carried out a further study in healthy volunteers in which we compared the relative systemic bioavailability of FP/SM in combination via unwashed but primed Volumatic spacer, Synchro-Breathe and pMDI devices [7] . When compared to the Seretide pMDI device, the unwashed but primed Volumatic spacer resulted in a 1.66-fold (40%) and the breath actuated Synchro-Breathe device resulted in a 1.75-fold (43%) greater suppression of OUCC. In terms of the SM moiety, the Volumatic and Synchro-Breathe devices resulted in a 4.7 and 6% greater fall in K, respectively, compared to pMDI. A comparison of our previous results with those of this study would suggest that when initially using new conventional spacers, the presence of an electrostatic charge does not have a significant negative impact on lung delivery of FP/SM. We believe that the use of eight serial puffs of Seretide pMDI in our study resulted in progressive priming of the spacer device over a short period of time and, hence, the observed improvements in lung delivery of each active moiety. Therefore, if this observation is translated into day-to-day clinical practice, the use of two puffs twice a day for 2 days (i.e. 8 puffs) via a spacer would adequately negate the effects of electrostatic charge on respirable dose delivery. In this regard, it is important to recognise that FP exhibits unique lung absorption characteristics that are influenced by the effects of the airway calibre and its high lipophilicity. The systemic lung absorption of inhaled FP is therefore higher in healthy volunteers and mild asthmatics who have a normal or near-normal airway calibre, as compared to more severe asthmatics who have attenuated systemic effects due to reduced lung function and possibly increased mucociliary clearance from central airways [18] . This protective effect of impaired lung function on FP systemic bioavailability has been previously studied by Lee et al. [18] . These researchers demonstrated that in severe asthmatics with a mean FEV1 (predicted forced expiratory volume in 1 s) of 47%, 2000 mcg of FP delivered via a primed Volumatic spacer for 2 weeks did not lead to the suppression of plasma cortisol levels or OUCC, in contrast to normal controls, thereby demonstrating the protective effects of reduced airway calibre and increased severity on the systemic hypothalamic pituitary axis (HPA). We believe that comparisons of FP lung bioavailability between healthy volunteers and asthmatics are valid across a range of severities when comparing different spacer devices as the relative ratio of OUCC suppression will be similar across the two groups, despite there being less absolute OUCC suppression in severe asthmatics. Time course data over 1 h was used to evaluate the systemic beta-2 adrenoreceptor response for the SM moiety. The obtained values indicated that there were significant early increases in heart rate, a fall in diastolic blood pressure and an increase in systolic blood pressure with all spacers, including the pMDI, with a numerical trend favouring the Synchro-Breathe device (Fig. 5) . These results suggest that there is rapid drug absorption across the alveolar capillary barrier and are in agreement with those reported previously which have confirmed that most of the systemic effects of inhaled SM are due to lung absorption [12] .The cardiac effects are presumed to be due to its direct effects on cardiac beta-2 adrenoreceptors and on beta-2-mediated dilatation of peripheral arteries. Indeed, SM has a steep dose response curve for its cardiac effects, and these effects are therefore highly sensitive but not necessarily specific enough to enable comparisons between devices [19, 20] . The metabolic response of an early fall in serum K has been shown to be a more reliable surrogate and enabled relevant comparisons between devices as the dose given was not at the top of the dose response curve; room for greater falls in serum K with higher doses has been demonstrated by Kempsford et al. [13] . Our results indicate that only the Aerochamber Plus, Volumatic and SynchroBreathe devices resulted in a statistically significant fall in K from baseline, with a numerical non-significant trend in favour of the Synchro-Breathe device. However, we were unable to replicate a significant difference in SM systemic bioavailability between the spacers and pMDI which we had demonstrated earlier. In this regard, the wider confidence intervals indicate that larger studies should be carried out before any definite deductions can be made.
It is important to clarify that we did not attempt to evaluate the anti-asthmatic efficacy of the FP/SM combination via the different delivery devices, as we only gave single doses of FP/SM. We recognise that the dose of FP/SM used was significantly higher than the normal dose, but this was essential to demonstrate assay sensitivity as we were ultimately able to separate out spacers from the pMDI, and at lower doses the signal from FP/SM would have been too small to make meaningful comparisons. Further, when interpreting lung bioavailability studies, it is also important to recognise that there are several factors which influence systemic lung bioavailability. These include the type of inhaled steroid/ long-acting beta agonist being used, the lipophilicity of the compound, the formulation, the type of actuator, the use of adjunctive devices, such as spacers and, more importantly, the technique of drug inhalation.
We have used the spacers brand new with optimal inhalation technique and, hence, the observed differences are likely to be a more relevant in day-to-day clinical practice. We recognise that increased lung dose delivery with spacer devices is a double-edged sword as it can on the one hand lead to greater clinical efficacy at perhaps lower nominal doses with fewer local adverse effects but, on the other hand, it can potentially increase the systemic adverse effect burden with chronic dosing, particularly with FP. However, this is less likely to be a problem with SM due to the tachyphylaxis of response as a result of beta-2 adrenoreceptor downregulation and sub-sensitivity with chronic dosing [21] .
Conclusion
In conclusion, we have demonstrated that the novel breathactuated Synchro-Breathe device is comparable to new small volume Aerochamber Plus and large volume Volumatic spacers in terms of improvements in relative lung delivery of combined FP/SM. The use of serial puffs, as used in real life, counteracts the effects of electrostatic charge on the respirable drug delivery of FP/SM (as early as day 2 when using two puffs FP/SM pMDI twice daily) by effecting progressive priming and suggests that conventional plastic spacer devices can be used out of the box without any need for prewashing or priming.
